Literature DB >> 12464679

T cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+/K+-ATPase.

Mark W Musch1, Lane L Clarke, Daniel Mamah, Lara R Gawenis, Zheng Zhang, William Ellsworth, David Shalowitz, Navdha Mittal, Petros Efthimiou, Ziad Alnadjim, Steve D Hurst, Eugene B Chang, Terrence A Barrett.   

Abstract

Inflammatory bowel disease (IBD) is associated with mucosal T cell activation and diarrhea. We found that T cell activation with anti-CD3 mAb induces profound diarrhea in mice. Diarrhea was quantified by intestinal weight-to-length (wt/l) ratios, mucosal Na(+)/K(+)-ATPase activity was determined and ion transport changes were measured in Ussing chambers. Anti-CD3 mAb increased jejunal wt/l ratios by more than 50% at 3 hours, returning to base line after 6 hours. Fluid accumulation was significantly reduced in TNF receptor-1 (TNFR-1(-/-)), but not IFN-gamma knockout mice. Anti-CD3 mAb decreased mucosal Na(+)/K(+)-ATPase activity, which was blocked by anti-TNF mAb and occurred to a lesser degree in TNFR-1(-/-) mice. Neither alpha nor beta subunits of Na(+)/K(+)-ATPase decreased in abundance at 3 hours. Intestinal tissue from anti-CD3-treated mice exhibited increased permeability to mannitol at 1 hour and decreases in electroneutral Na(+) absorption, Na(+)-dependent glucose absorption, and cAMP-stimulated anion secretion at 3 hours. Furthermore, enteral fluid accumulation was observed in CFTR(-/-) mice, indicating a minor role of active anion secretion. These data suggest that diarrhea in IBD is due to TNF-mediated malabsorption rather than to secretory processes. T cell activation induces luminal fluid accumulation by increasing mucosal permeability and reducing epithelial Na(+)/K(+)-ATPase activity leading to decreased intestinal Na(+) and water absorption.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464679      PMCID: PMC151630          DOI: 10.1172/JCI15695

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.

Authors:  W A Stack; S D Mann; A J Roy; P Heath; M Sopwith; J Freeman; G Holmes; R Long; A Forbes; M A Kamm
Journal:  Lancet       Date:  1997-02-22       Impact factor: 79.321

2.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Authors:  F J Baert; G R D'Haens; M Peeters; M I Hiele; T F Schaible; D Shealy; K Geboes; P J Rutgeerts
Journal:  Gastroenterology       Date:  1999-01       Impact factor: 22.682

3.  Tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta 1 (TGF-beta 1) inhibit the expression and activity of Na+/K(+)-ATPase in FRTL-5 rat thyroid cells.

Authors:  A E Pekary; S R Levin; D G Johnson; L Berg; J M Hershman
Journal:  J Interferon Cytokine Res       Date:  1997-04       Impact factor: 2.607

4.  Tumor necrosis factor-alpha and interleukin-6 in stools of children with bacterial and viral gastroenteritis.

Authors:  N Kutukculer; S Caglayan
Journal:  J Pediatr Gastroenterol Nutr       Date:  1997-11       Impact factor: 2.839

5.  Mechanism of inhibition of Na+-glucose cotransport in the chronically inflamed rabbit ileum.

Authors:  U Sundaram; S Wisel; V M Rajendren; A B West
Journal:  Am J Physiol       Date:  1997-10

6.  Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease.

Authors:  G R Brown; G Lindberg; J Meddings; M Silva; B Beutler; D Thiele
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

7.  Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease.

Authors:  E M Nilsen; F L Jahnsen; K E Lundin; F E Johansen; O Fausa; L M Sollid; J Jahnsen; H Scott; P Brandtzaeg
Journal:  Gastroenterology       Date:  1998-09       Impact factor: 22.682

8.  Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis.

Authors:  H Schmitz; C Barmeyer; M Fromm; N Runkel; H D Foss; C J Bentzel; E O Riecken; J D Schulzke
Journal:  Gastroenterology       Date:  1999-02       Impact factor: 22.682

9.  Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

Authors:  R C Evans; L Clarke; P Heath; S Stephens; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

10.  Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger.

Authors:  P J Schultheis; L L Clarke; P Meneton; M L Miller; M Soleimani; L R Gawenis; T M Riddle; J J Duffy; T Doetschman; T Wang; G Giebisch; P S Aronson; J N Lorenz; G E Shull
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

View more
  70 in total

1.  Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors.

Authors:  Qais Al-Awqati
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 2.  Myosin light chain kinase: pulling the strings of epithelial tight junction function.

Authors:  Kevin E Cunningham; Jerrold R Turner
Journal:  Ann N Y Acad Sci       Date:  2012-07       Impact factor: 5.691

3.  Cytokine regulation of OCTN2 expression and activity in small and large intestine.

Authors:  Mikihiro Fujiya; Yuhei Inaba; Mark W Musch; Shien Hu; Yutaka Kohgo; Eugene B Chang
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

4.  Differential gene expression and functional analysis implicate novel mechanisms in enteric nervous system precursor migration and neuritogenesis.

Authors:  Bhupinder P S Vohra; Keiji Tsuji; Mayumi Nagashimada; Toshihiro Uesaka; Daniel Wind; Ming Fu; Jennifer Armon; Hideki Enomoto; Robert O Heuckeroth
Journal:  Dev Biol       Date:  2006-06-27       Impact factor: 3.582

5.  T cell activation alters intestinal structure and function.

Authors:  Michael Field
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

6.  Epithelial apoptosis in mechanistically distinct methods of injury in the murine small intestine.

Authors:  D Vyas; C M Robertson; P E Stromberg; J R Martin; W M Dunne; C W Houchen; T A Barrett; A Ayala; M Perl; T G Buchman; C M Coopersmith
Journal:  Histol Histopathol       Date:  2007-06       Impact factor: 2.303

7.  Tumor necrosis factor-alpha and interferon-gamma increase PepT1 expression and activity in the human colon carcinoma cell line Caco-2/bbe and in mouse intestine.

Authors:  Stephan R Vavricka; Mark W Musch; Mikihiro Fujiya; Keri Kles; Laura Chang; Jyrki J Eloranta; Gerd A Kullak-Ublick; Ken Drabik; Didier Merlin; Eugene B Chang
Journal:  Pflugers Arch       Date:  2005-11-19       Impact factor: 3.657

8.  Therapeutic benefit of pentostatin in severe IL-10-/- colitis.

Authors:  Jeffrey B Brown; Goo Lee; Gery R Grimm; Terrence A Barrett
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

9.  Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression.

Authors:  Micah N Zuhl; Kathryn R Lanphere; Len Kravitz; Christine M Mermier; Suzanne Schneider; Karol Dokladny; Pope L Moseley
Journal:  J Appl Physiol (1985)       Date:  2013-11-27

10.  Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria.

Authors:  Ruhul Amin; John Asplin; Daniel Jung; Mohamed Bashir; Altayeb Alshaikh; Sireesha Ratakonda; Sapna Sharma; Sohee Jeon; Ignacio Granja; Dietrich Matern; Hatim Hassan
Journal:  Kidney Int       Date:  2018-02-01       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.